http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Rubio Juan Manuel (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
Juan M. León-Martínez,Esperanza Martínez-Abundis,Manuel González-Ortiz,Karina G. Pérez-Rubio 한국식품영양과학회 2021 Journal of medicinal food Vol.24 No.2
To evaluate the effect of berberine (BBR) plus bezafibrate administration on the lipid profile of patients with mixed dyslipidemia. A double-blind randomized pilot clinical trial with parallel groups was carried out in 36 patients, aged 30–60 years with mixed dyslipidemia [triglycerides (TG) ≥1.7 mM and total cholesterol (TC) ≥5.2 mM]. Patients were assigned to 3 groups of 12 patients each, receiving oral administration during 90 days of BBR 500 mg t.i.d., bezafibrate 400 mg b.i.d., or BBR 500 mg t.i.d. plus bezafibrate 400 mg b.i.d, respectively. Clinical evaluation, lipid profile, glucose, creatinine, and uric acid levels were measured before and after the pharmacological intervention. Kruskal–Wallis, Wilcoxon, Mann–Whitney U, and χ2 tests were used for statistical analyses; a P ≤ .05 was considered statistically significant. BBR reduced TC levels. Bezafibrate decreased TG, TC, low-density lipoprotein cholesterol (LDL-C), and very low-density lipoprotein (VLDL) concentrations. BBR plus bezafibrate decreased TG (2.6 ± 0.8 vs. 1.3 ± 0.7 mM, P = .007), TC (6.3 ± 0.7 vs. 4.6 ± 1.2 mM, P = .005), LDL-C (3.4 ± 0.6 vs. 2.2 ± 1.3 mM, P = .037), and VLDL (0.5 ± 0.2 vs. 0.2 ± 0.1 mM, P = .007) levels. Bezafibrate and BBR plus bezafibrate significantly decreased TG, TC, LDL-C, and VLDL concentrations, and thus, remitting the diagnosis of mixed dyslipidemia in 90% of the patients.
-
Rufino Mondejar,Jose Manuel Garcia-Moreno,Rocio Rubio,Francisca Solano,Mercedes Delgado,Begona Garcia-Bravo,Juan Jose Rios-Martin,Amalia Martinez-Mir,Miguel Lucas 대한신경과학회 2014 Journal of Clinical Neurology Vol.10 No.1
Background Lipoid proteinosis (LP) is a rare autosomal recessive disorder characterized bya hoarse voice, variable scarring, and infiltration of the skin and mucosa. This disease is associated with mutations of the gene encoding extracellular matrix protein 1 (ECM1). Case Report This was a clinical and molecular study of a new case of LP with a severe phenotype. A 35-year-old female born to nonconsanguineous parents developed dermatologicaland extracutaneous symptoms in her 9th month of life. The neurological abnormalities of thedisease began to appear at the age of 19 years. Computed tomography revealed cranial calcifications. Conclusions The diagnosis of LP was confirmed by histopathological findings and direct sequencing of ECM1. A new homozygous nonsense mutation was identified in exon 7 of ECM1, c.1076G>A (p.Trp359*). This mutation was not detected in 106 chromosomes of healthy individuals with a similar demographic origin. Microsatellite markers around ECM1 were used to construct the haplotype in both the parents and the patient. Reports on genotype-phenotype correlations in LP point to a milder phenotype in carriers of missense mutations in the Ecm1a isoform, whereas mutations in the Ecm1b isoform are thought to be associated with more severe phenotypes. The present findings in a Spanish patient carrying a truncating mutation in exon 7 revealed complete dermatological and neurological manifestations.
-
Adriana Saldana-Robles,Juan M. Peralta-Hernandez,Ricardo Guerra-Sanchez,Manuel I. Maldonado-Rubio 한국공업화학회 2014 Journal of Industrial and Engineering Chemistry Vol.20 No.3
This study focused on the application of RSM on the Fenton process and the adsorption of vegetal carbon(VC) to obtain the optimal conditions for the minimization of the colored synthetic wastewater. Methylorange (MO) with an azo dye was used as the model organic compound. Fenton processes wereinvestigated to establish the optimal conditions. The Fe2+/H2O2 ratio was studied to establish the majorMO degradation when 100 and 200 mg/L of MO were treated. For the adsorption process, to determinethe optimal conditions, the principal variables studied were the vegetal carbon mass dosage, degradationtime and dye concentration.
-
Salguero Joseba,Gómez-Gómez Enrique,Valero-Rosa José,Carrasco-Valiente Julia,Mesa Juan,Martin Cristina,Campos-Hernández Juan Pablo,Rubio Juan Manuel,López Daniel,Requena María José 대한영상의학회 2021 Korean Journal of Radiology Vol.22 No.4
Objective: To evaluate the impact of multiparametric magnetic resonance imaging (mpMRI) before confirmatory prostate biopsy in patients under active surveillance (AS). Materials and Methods: This retrospective study included 170 patients with Gleason grade 6 prostate cancer initially enrolled in an AS program between 2011 and 2019. Prostate mpMRI was performed using a 1.5 tesla (T) magnetic resonance imaging system with a 16-channel phased-array body coil. The protocol included T1-weighted, T2-weighted, diffusion-weighted, and dynamic contrast-enhanced imaging sequences. Uroradiology reports generated by a specialist were based on prostate imagingreporting and data system (PI-RADS) version 2. Univariate and multivariate analyses were performed based on regression models. Results: The reclassification rate at confirmatory biopsy was higher in patients with suspicious lesions on mpMRI (PI-RADS score ≥ 3) (n = 47) than in patients with non-suspicious mpMRIs (n = 61) and who did not undergo mpMRIs (n = 62) (66%, 26.2%, and 24.2%, respectively; p < 0.001). On multivariate analysis, presence of a suspicious mpMRI finding (PI-RADS score ≥ 3) was associated (adjusted odds ratio: 4.72) with the risk of reclassification at confirmatory biopsy after adjusting for the main variables (age, prostate-specific antigen density, number of positive cores, number of previous biopsies, and clinical stage). Presence of a suspicious mpMRI finding (adjusted hazard ratio: 2.62) was also associated with the risk of progression to active treatment during the follow-up. Conclusion: Inclusion of mpMRI before the confirmatory biopsy is useful to stratify the risk of reclassification during the biopsy as well as to evaluate the risk of progression to active treatment during follow-up.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
